Associated tags: Adverum Biotechnologies, Standard of care, Paratriathlon, Patient, IVT, Research, Neovascularization, Biotechnology, Pharmaceutical industry, AMD, Safety
Locations: NEW YORK, REDWOOD, CALIFORNIA, LUNA, LOS ANGELES, SAN FRANCISCO, ONGO, LINDA, FLORIDA, WALL STREET, REDWOOD CITY, CA, US, SWEDEN
Adverum Biotechnologies,
FDA,
AMD,
Patient,
Inflammation,
Retinitis,
Investment,
Safety,
CST,
Research,
Chorioretinitis,
Compensated emancipation,
Vascular occlusion,
Employment,
Macula,
Episcleritis,
Data,
OPTIC,
Three Months,
Vasculitis,
Society,
LUNA,
Intraocular pressure,
VEGF,
ASRS,
Injection,
Pharmaceutical industry REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the first quarter of 2024. The company also provided recent pipeline highlights.
Key Points:
- “Our presentation will feature a 26-week landmark interim analysis, which is expected to serve as the basis of our FDA end-of-Phase 2 meeting.
- The award was granted under the Adverum Biotechnologies, Inc. 2017 Inducement Plan, as amended and restated, and will vest over four years, subject to continued service with Adverum.
- Stock-based compensation expense included in research and development expenses was $1.1 million for the first quarter of 2024.
- Stock-based compensation expense included in general and administrative expenses was $3.0 million for the first quarter of 2024.
BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.
Key Points:
- BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.
- H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 11:00 a.m.
- The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website.
- A replay of the webcast will be available on the website for at least 30 days following the presentation.
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.
Key Points:
- REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.
- Title: Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
The presentation will be available on the News and Publications section of Adverum’s website shortly after the presentation.
Research,
Adverum Biotechnologies,
Vasculitis,
Three Months,
Macula,
Chorioretinitis,
Inflammation,
Patient,
Episcleritis,
American Academy,
Anti-VEGF,
LUNA,
Intraocular pressure,
Investment,
Clinical trial,
Injection,
Safety,
Drug development,
Paratriathlon,
AMD,
AAO,
OPTIC,
Retinitis,
CST,
Vascular occlusion,
Annual general meeting,
VEGF,
Pharmaceutical industry REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.
Key Points:
- The company also provided recent pipeline highlights and corporate updates.
- 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
- Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
- Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.
Retrieved on:
Wednesday, February 28, 2024
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m.
Key Points:
- REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m.
- ET.
- The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website.
- A replay of the webcast will be available on the website for at least 30 days following the presentation.
Retrieved on:
Friday, February 16, 2024
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Retrieved on:
Monday, February 12, 2024
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m.
Key Points:
- REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m.
- ET.
- The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website.
- A replay of the webcast will be available on the website for at least 30 days following the presentation.
Retrieved on:
Thursday, February 8, 2024
Chorioretinitis,
Injection,
Principal,
Inflammation,
Life,
Adverum Biotechnologies,
VEGF,
AMD,
Partner (business rank),
Vasculitis,
Patient,
Safety,
Paratriathlon,
Prednisone,
University of Nevada, Reno,
Intraocular pressure,
Data,
Webcast,
University,
Retinitis,
M.A,
Clinical research,
CST,
Vascular occlusion,
Pharmaceutical industry These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
Key Points:
- These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
- “Wet AMD is a leading cause of blindness in people over the age of 65, requiring life-long anti-VEGF injections.
- Our goal with Ixo-vec is to provide patients virtually injection-free management of their wet AMD lasting years and potentially for life,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
- The LUNA trial builds on our experience with the OPTIC study, where landmark 2-year data was recently published in The Lancet’s eclinicalmedicine.
Retrieved on:
Tuesday, February 6, 2024
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $1.20, representing a premium of approximately 20% to Adverum’s 30-day volume-weighted average price. The financing is expected to close on February 8, 2024, subject to customary closing conditions. Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses.
Key Points:
- The financing is expected to close on February 8, 2024, subject to customary closing conditions.
- Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses.
- The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, are expected to be sufficient to fund the current operating plan into late 2025.
- Adverum has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in this private placement.
